tiprankstipranks
Trending News
More News >
Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
US Market
Advertisement

Caris Life Sciences, Inc. (CAI) Stock Forecast & Price Target

Compare
53 Followers
See the Price Targets and Ratings of:

CAI Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Caris
Life Sciences, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CAI Stock 12 Month Forecast

Average Price Target

$32.86
▲(23.95%Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Caris Life Sciences, Inc. in the last 3 months. The average price target is $32.86 with a high forecast of $38.00 and a low forecast of $31.00. The average price target represents a 23.95% change from the last price of $26.51.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","32":"$32","39":"$39","28.5":"$28.5","35.5":"$35.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,28.5,32,35.5,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.51,27.393846153846155,28.27769230769231,29.161538461538463,30.045384615384616,30.92923076923077,31.813076923076924,32.69692307692308,33.580769230769235,34.464615384615385,35.348461538461535,36.23230769230769,37.11615384615385,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.51,26.99846153846154,27.486923076923077,27.975384615384616,28.463846153846156,28.95230769230769,29.44076923076923,29.92923076923077,30.417692307692306,30.906153846153845,31.394615384615385,31.88307692307692,32.371538461538464,{"y":32.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.51,26.855384615384615,27.200769230769232,27.546153846153846,27.891538461538463,28.236923076923077,28.582307692307694,28.927692307692308,29.273076923076925,29.61846153846154,29.963846153846156,30.30923076923077,30.654615384615383,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.25,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$38.00Average Price Target$32.86Lowest Price Target$31.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wolfe Research Analyst forecast on CAI
Doug SchenkelWolfe Research
Wolfe Research
$32
Buy
20.71%
Upside
Initiated
07/14/25
Caris Life Sciences initiated with an Outperform at Wolfe ResearchCaris Life Sciences initiated with an Outperform at Wolfe Research
TD Cowen
$32
Buy
20.71%
Upside
Initiated
07/14/25
Strong Sales Growth and Strategic Market Expansion Drive Buy Rating for Caris Life Sciences
Citi
$34
Buy
28.25%
Upside
Initiated
07/14/25
Caris Life Sciences initiated with a Buy at CitiCaris Life Sciences initiated with a Buy at Citi
Bank of America Securities Analyst forecast on CAI
Michael RyskinBank of America Securities
Bank of America Securities
$31
Buy
16.94%
Upside
Initiated
07/14/25
Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating
J.P. Morgan Analyst forecast on CAI
Rachel VatnsdalJ.P. Morgan
J.P. Morgan
$31
Buy
16.94%
Upside
Initiated
07/14/25
Caris Life Sciences initiated with an Overweight at JPMorganCaris Life Sciences initiated with an Overweight at JPMorgan
Guggenheim Analyst forecast on CAI
Subbu NambiGuggenheim
Guggenheim
$32
Buy
20.71%
Upside
Initiated
07/13/25
Caris Life Sciences initiated with a Buy at GuggenheimCaris Life Sciences initiated with a Buy at Guggenheim
BTIG
$38
Buy
43.34%
Upside
Initiated
07/13/25
Caris Life Sciences initiated with a Buy at BTIGCaris Life Sciences initiated with a Buy at BTIG
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wolfe Research Analyst forecast on CAI
Doug SchenkelWolfe Research
Wolfe Research
$32
Buy
20.71%
Upside
Initiated
07/14/25
Caris Life Sciences initiated with an Outperform at Wolfe ResearchCaris Life Sciences initiated with an Outperform at Wolfe Research
TD Cowen
$32
Buy
20.71%
Upside
Initiated
07/14/25
Strong Sales Growth and Strategic Market Expansion Drive Buy Rating for Caris Life Sciences
Citi
$34
Buy
28.25%
Upside
Initiated
07/14/25
Caris Life Sciences initiated with a Buy at CitiCaris Life Sciences initiated with a Buy at Citi
Bank of America Securities Analyst forecast on CAI
Michael RyskinBank of America Securities
Bank of America Securities
$31
Buy
16.94%
Upside
Initiated
07/14/25
Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating
J.P. Morgan Analyst forecast on CAI
Rachel VatnsdalJ.P. Morgan
J.P. Morgan
$31
Buy
16.94%
Upside
Initiated
07/14/25
Caris Life Sciences initiated with an Overweight at JPMorganCaris Life Sciences initiated with an Overweight at JPMorgan
Guggenheim Analyst forecast on CAI
Subbu NambiGuggenheim
Guggenheim
$32
Buy
20.71%
Upside
Initiated
07/13/25
Caris Life Sciences initiated with a Buy at GuggenheimCaris Life Sciences initiated with a Buy at Guggenheim
BTIG
$38
Buy
43.34%
Upside
Initiated
07/13/25
Caris Life Sciences initiated with a Buy at BTIGCaris Life Sciences initiated with a Buy at BTIG
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Caris Life Sciences, Inc.

1 Month
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+18.00%
initiated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +18.00% per trade.
3 Months
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+18.00%
initiated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +18.00% per trade.
1 Year
Subbu NambiGuggenheim
Success Rate
1/1 ratings generated profit
100%
Average Return
+18.40%
initiated a buy rating 6 days ago
Copying Subbu Nambi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.40% per trade.
2 Years
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+18.00%
initiated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +18.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CAI Analyst Recommendation Trends

Rating
Jul 25
Strong Buy
0
Buy
6
Hold
0
Sell
0
Strong Sell
0
total
6
In the current month, CAI has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CAI average Analyst price target in the past 3 months is 32.86.
Each month's total comprises the sum of three months' worth of ratings.

CAI Financial Forecast

No data currently available

CAI Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.
No data currently available

CAI Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

CAI Stock Forecast FAQ

What is CAI’s average 12-month price target, according to analysts?
Based on analyst ratings, Caris Life Sciences, Inc.’s 12-month average price target is 32.86.
    What is CAI’s upside potential, based on the analysts’ average price target?
    Caris Life Sciences, Inc. has 23.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CAI a Buy, Sell or Hold?
          Caris Life Sciences, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Caris Life Sciences, Inc.’s price target?
            The average price target for Caris Life Sciences, Inc. is 32.86. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $38.00 ,the lowest forecast is $31.00. The average price target represents 23.95% Increase from the current price of $26.51.
              What do analysts say about Caris Life Sciences, Inc.?
              Caris Life Sciences, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of CAI?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis